Inhibition of HIV-1 Replication by Secondary Metabolites From Endophytic Fungi of Desert Plants
Brian P. Wellensiek1, +, Rajesh Ramakrishnan1, ++, Bharat P. Bashyal2, Yvette Eason1, A. A. Leslie Gunatilaka2, Nafees Ahmad*, 1
Identifiers and Pagination:Year: 2013
First Page: 72
Last Page: 80
Publisher Id: TOVJ-7-72
Article History:Received Date: 8/5/2013
Revision Received Date: 24/5/2013
Acceptance Date: 14/6/2013
Electronic publication date: 26/7/2013
Collection year: 2013
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Most antiretroviral drugs currently in use to treat an HIV-1 infection are chemically synthesized and lead to the development of viral resistance, as well as cause severe toxicities. However, a largely unexplored source for HIV-1 drug discovery is endophytic fungi that live in a symbiotic relationship with plants. These fungi produce biologically active secondary metabolites, which are natural products that are beneficial to the host. We prepared several hundred extracts from endophytic fungi of desert plants and evaluated the inhibitory effects on HIV-1 replication of those extracts that showed less than 30% cytotoxicity in T-lymphocytes. Those extracts that inhibited viral replication were fractionated in order to isolate the compounds responsible for activity. Multiple rounds of fractionation and antiviral evaluation lead to the identification of four compounds, which almost completely impede HIV-1 replication. These studies demonstrate that metabolites from endophytic fungi of desert plants can serve as a viable source for identifying potent inhibitors of HIV-1 replication.
Several strides have been made in understanding the molecular mechanisms of pathogenesis of human immunodeficiency virus type 1 (HIV-1) infection since the discovery of the virus in 1983 [1, 2]. This understanding has highlighted several critical points in the HIV-1 lifecycle that can be targeted for development of anti-retroviral drugs . Along these lines, many anti-retroviral drugs have been developed to target the viral enzymes reverse transcriptase, integrase and protease, as well as the viral proteins which facilitate entry into the host cell . When used in a clinical setting, these drugs have been shown to greatly reduce viral load and significantly improve patient survival. However, due to the relatively high mutation rate associated with HIV-1 replication, continued exposure of the virus to a specific antiviral leads to the development of drug-resistant viral strains. This, in turn, creates a need to treat patients with an ever-changing regimen of drugs, all of which have several toxic side effects . These factors create treatment options which are not ideal, and can lead to barriers that hinder effective management of the infection. The development of new antiviral drugs that are able to sufficiently inhibit HIV-1 replication with little adverse side effects is tantamount if there is to be any progress towards stopping the HIV-1 epidemic.
Most anti-retroviral drugs used today are chemically synthesized in laboratories. While this approach has resulted in drugs that can inhibit HIV-1 and be produced relatively easily, these drugs have not been able to provide a way to completely prevent or terminate an HIV-1 infection in patients as well as avoid side effects and development of resistance. Optimization of these existing drugs is clearly important work but may never fully alleviate the problems in using them for treatment. However, exploring new avenues of drug discovery could lead to the development of more ideal treatment or prevention options. A relatively untapped resource for anti-HIV-1 drug discovery lies in natural products found in plants and their associated fungi . These products of natural origin have been studied in the context of other diseases, such as cancer, and several chemotherapeutic drugs have resulted from these studies [7, 8]. In fact, approximately 60% of the anticancer and anti-infective agents which are commercially available are of natural origin .
A source of several natural products has been the endophytic fungi that live within desert plants . These fungi reside within the stems, roots and leaves of plants in a symbiotic relationship. The plant protects and feeds the fungi, which in turn produces bioactive (plant growth regulatory, antibacterial, antifungal, antiviral, insecticidal, antidrought, anticold, antiheat) substances to enhance the growth and competitiveness of the plant and to protect it from herbivores and plant pathogens . These bioactive substances have been isolated and characterized, leading to the development of drugs such as Taxol (anticancer) , Cryptocandin (antimycotic) , Preussomerin D (antimicrobial)  and Sequoiatone A and B (antitumor) . Some studies have identified substances that inhibit viruses [16, 17], specifically the cytonic acids A and B isolated from endophytic fungi were found to inhibit the human cytomegalovirus protease enzyme . However, the effect of compounds from endophytic fungi on anti-viral activity, especially anti-HIV, has been largely unexplored [19, 20]. It is apparent that the potential for the discovery of compounds having antiviral activity from endophytic fungi is in its infancy. To this end, we have employed tissue culture assays to evaluate the inhibitory properties of crude extracts, fractions, and compounds from the endophytic fungi of desert plants on an HIV-1 infection. We evaluated several hundred extracts from endophytic fungi and identified a number of compounds from these extracts that completely (100%) inhibit HIV-1 replication in T-lymphocytes. These results show promise towards developing new non-toxic and potent anti-HIV drugs from endophytic fungi.
Evaluation of Antiviral Capabilities of Endophytic Fungal Extracts
We first determined the cytotoxicity of the endophytic fungal extracts in T-lymphocytes. Each of the fungal extracts was evaluated for cytotoxicity by incubating (a T4-lymphocyte cell line) with various concentrations of the extracts over a period of nine days. The toxic effects to the A3.01 cells were determined every three days using the MTT assay. Varying cytoxicity levels were seen when evaluating the individual fungal extracts. When observed, the highest levels of toxicity occurred on day nine of culture, and all cytotoxicity values given refer to toxicity observed on this day. Several hundred extracts were evaluated, however only extracts that displayed 30% toxicity or less were chosen for further studies, and 100 extracts were found to meet this requirement. Initial experiments revealed that extracts CS, CT, B, G, and I displayed low levels of toxicity towards A3.01 cells at a concentration of 2 μg/mL, resulting in 25%, 19%, 10%, 15% and 22% cell death respectively, when compared to non-treated cells (data not shown).
Based on the toxicity results the effects of these extracts on HIV-1 replication was determined by infecting A3.01 cells with HIV-1LAV in the presence of the extracts at a 2 μg/mL concentration. The inhibition levels of the extracts tested were determined by comparison with the DMSO (solvent) control at peak days of virus production. Azidothymidine (AZT), a known reverse transcriptase inhibitor , was used as positive control. The level of viral replication present in each culture was measured using the reverse transcriptase (RT) assay every three days until viral replication began to naturally decrease. Each of these extracts inhibited HIV-1 replication to varying degrees. Approximately half (52) of the extracts tested resulted in inhibition between 0 and 25%, another 25 showed 25-50% inhibition, 19 inhibited viral replication from 50 to 75%, and only 4 displayed inhibition between 75 and 99%. A representative graph is shown in Fig. (1). Extracts CS and CT each resulted in around 25% inhibition of HIV-1 replication. Extract I inhibited replication by 38%, and interestingly, extracts B and G inhibited viral replication almost completely (96 and 99%). In the case of extracts B and G, the levels of virus present in culture supernatants were just above that of the uninfected (mock) control. Based on these results, extracts B, G and I were chosen for further investigation.
Evaluation of Large Scale Endophytic Fungal Extracts and Fractions
In order to evaluate the individual compounds within the fungal extracts that were responsible for conveying antiviral capabilities, extracts B, G and I were fractionated. A diagram detailing the full fractionation of these extracts is shown in Fig. (2). The fungal cultures were grown on a large scale to obtain sufficient extracts for fractionation. These large-scale extracts and fractions were then evaluated for cytotoxicity using the MTT assay as before at concentrations of 2, 4, 8, and 16 μg/mL. This spread of concentrations was used, as it was believed that the toxic concentrations of the individual fractions would vary from the unfractionated extracts. As can be seen in Fig. (3a), the toxicity of the large scale extracts and fractions increased in a dose dependent manner. Toxicity of each large-scale extract and fraction was determined as percent of cellular survival compared to the solvent control, which contained the concentration of DMSO that was present in each large-scale extract/fraction culture. Each large-scale extract and fraction was not toxic at 2 or 4 μg/mL, except for DB-2, which showed 44% toxicity. At 8 μg/mL, all of the tested extracts were not toxic except the large-scale extract DB (83% toxicity) and its fraction DB-2 (89% toxicity). When the concentration was increased to 16 μg/mL toxicity levels varied from 85% with DB-2 to 8% with DC-3. The observed toxicities were not due to the presence of DMSO in the cultures as no toxicity was seen in the solvent control (Fig. 3a).
Based on these cytotoxicity results, concentrations for the evaluation of these large scale extracts and fractions on HV-1 replication were chosen. All samples, except for DB and DB-2, were tested at a concentration of 8 μg/mL. Large-scale extract DB was evaluated at a concentration of 2 μg/mL, while DB-2 was tested at concentrations of 0.25, 0.5 and 1 μg/mL. Inhibition of viral replication was carried out as before by the infection of A3.01 cells in the presence of the large-scale extract or its fraction. All samples, except fraction DB-3, showed the ability to inhibit HIV-1 replication to some degree (Fig. 3b). Inhibition ranged from 17% with DC-2, to almost 100% inhibition with the large scale extract DB. This inhibition was comparable to the levels of inhibition by the reverse transcriptase inhibitor AZT. The inhibitory capabilities of DB appear to be derived from the fraction DB-2, which inhibited viral replication almost completely at the day of peak virus production in the solvent control, and delayed the peak of virus production by 6 days (Fig. 3b).
Evaluation of DB-2 Fractions
The fraction DB-2 displayed the largest amount of HIV-1 replication inhibition (Fig. 3b). As this fraction arose from only one round of fractionation of the large-scale extract DB, it was possible that more than one compound was present within DB-2. Therefore, DB-2 was subjected to a second round of fractionation to give rise to the fractions DD, DE, DF and DG. As DB-2 was toxic at lower concentrations in previous experiments (Fig. 3a), MTT assays were performed with DD, DE, DF and DG at lower concentrations of 0.1, 0.2, 0.5, 1 and 2 μg/mL (Fig. 4a). Fractions DD, DF, and DG displayed toxic effects only at the highest concentration tested (2 μg/mL). Fraction DE was toxic at 1μg/mL (70% toxicity), however was not toxic at 0.5 μg/mL. All the fractions were at least 70% toxic at a concentration of 2 μg/mL.
Using the above described cytotoxicity results as a guide, fractions DD, DE, DF and DG were evaluated for their ability to inhibit HIV-1 replication. DD, DF and DG were all tested at a concentration of 1 μg/mL, while DE was evaluated at 0.5 μg/mL. All of the fractions inhibited HIV-1 replication, with the lowest amount of inhibition occurring with DG at 35% (Fig. 4b). Fraction DF inhibited replication by 60%, while DD and DE displayed almost 100% inhibition at the day of peak virus production. This inhibition was greater than that of the known reverse transcriptase inhibitor AZT.
Evaluation of Pure Isolated Compounds
To isolate the individual compounds from DD, DE and DF, which all inhibited HIV-1 replication (Fig. 4b), the fractions underwent one final round of fractionation. The compounds displayed varying levels of toxicity when compared to the solvent control (Fig. 5a). Compound DK was not toxic at a concentration of 1.5 μg/mL, while compound DL reached acceptable toxicity levels at 0.5 μg/mL. Compounds DM, DN and DP were mildly toxic, with the greatest toxicity (31%) occurring at 1 μg/mL with DP. All compounds tested were almost completely toxic at 2 μg/mL, with the exception of DN, which was 46% toxic at that concentration.
Based on the cytotoxicity results, the individual compounds were evaluated for their ability to inhibit HIV-1 replication in A3.01 cells. Compounds DK, DM, DN and DP were tested at a concentration of 1.5 μg/mL, while DL was evaluated at 0.5 μg/mL. Compound DN inhibited viral replication by 33% at the peak day of viral production, while DK, DL, DM and DP inhibited viral replication almost completely (97-99%) (Fig. 5b). This inhibition was greater than that of the highest concentration of AZT, 97% at 20μM. In addition, RT counts were barely over that of the mock infected (no virus added to the culture) control.
Titration of Anti-HIV-1 Activity
At the highest non-cytotoxic dose possible, compounds DK, DL, DM and DP inhibit HIV-1 replication almost completely (Fig. 5a, b). To determine the minimum dose required for significant antiviral activity, each compound was screened at decreasing concentration intervals until viral replication increased (Fig. 6a-d). For all assays, antiviral activity was evaluated nine days post-infection, the day of peak viral replication in the untreated infection control. Low levels of viral replication began to appear at a concentration of 0.3 μg/mL for compound DK, which had a calculated 50% inhibitory concentration (IC50) of 0.1 μg/mL (Fig. 6a). Compounds DL and DM were more effective at lower concentrations, with noticeable viral replication at 0.1 and 0.075 μg/mL, and IC50’s of 0.075 and 0.03 μg/mL, respectively (Fig. 6b, c). Much higher concentrations were required for compound DP to be effective, with viral replication returning at a concentration of 0.75 μg/mL and an IC50 of 0.5 μg/mL (Fig. 6d). Combining the titration and cytotoxicity data for DK, DL, DM and DP, the therapeutic indexes for these compounds was determined to be 15, 6.5, 50, and 3, respectively.
Determination of Reverse Transcriptase Inhibition by Pure Endophytic Fungal Compounds
The compounds DK, DL, DM and DP all inhibited HIV-1 replication nearly 100% (Fig. 5b). As viral replication was measured by RT assay of the culture supernatant, the effect of these compounds on reverse transcriptase enzyme activity was determined to rule out false positives for viral replication inhibition. Aliquots of the same virus were used for each assay performed to assure that the same amount of virus was present, and each compound was evaluated at a concentration of 1.5 μg/mL. Upon determination of the levels of radioactive incorporation by RT enzyme activity, the compounds displayed little ability to inhibit RT function (Table 1). The maximum amount of inhibition seen was 6% with DM, however this 6% inhibition was also seen in the solvent (DMSO) control.
Effect of Endophytic Compounds on HIV-1 Reverse Transcriptase
|% RT Activity
|95 +/- 2
|100 +/- 10
|94 +/- 3
|100 +/- 1
|94 +/- 5
|100 +/- 0
|0 +/- 0
Inhibition of reverse transcriptase (RT) enzyme activity was determined by performing RT assays in the presence of the compounds DK, DM and DP at a concentration of 1.5 µg/mL, and DL at a concentration of 0.5 µg/mL. Controls for DMSO concentration present in compound wells (DMSO) and absence of compound (LAV) were included. A control with no virus present (mock) was also performed.
In this study, we have evaluated the effects of several hundred endophytic fungal extracts on HIV-1 replication in T-lymphocytes, the major target cell for HIV-1, and provide evidence that metabolites produced by these endophtic fungi possesses anti-retroviral activities. We have identified four non-toxic extracts that exhibited inhibitory effects on HIV-1 replication in the range of 75% to 99% in T-lymphocytes. In addition, three of these extracts were fractionated and fraction DB-2 completely inhibited HIV-1 replication at a concentration that was not cytotoxic. Moreover, further fractions of DB-2, including DD and DE, and DF inhibited HIV-1 replication by 100% and 60%, respectively. Furthermore, purified compounds DK, DL, DM and DP completely inhibited HIV-1 replication at concentrations of 0.5 – 1.5 μg/mL, which was comparable to the widely used antiretroviral drug AZT (azidothymidine) at a 20 μM concentration . This information demonstrates that metabolites from endophytic fungi can be potent inhibitors of HIV-1 replication and should be explored for new and non-toxic anti-HIV drug development.
The endophytic fungal species that the potent HIV-1 inhibitors were isolated from was Alternaria tenuissima, which inhabits the stem of the Sonoran desert plant Quercus emoryi. Early structure determination of these potent inhibitors revealed that the active compounds belong to a class of natural pigments known as perylenequinones. This class of pigments has previously been reported to have antiviral activity against herpes simplex virus type 1 and Sindbis virus  as well as protein kinase C inhibitory activity . A more elaborate structural analysis of these compounds is underway to determine specific protein domains involved in antiviral activity, and the details of this study will be presented in a separate communication.
Using endophytic fungal extracts for drug discovery has been extensively studied in other areas, such as cancer research , however the anti-HIV-1 potential of these extracts has been largely unexplored . To obtain the fungal extracts, several hundred endophytic fungi were isolated from various desert plants, and crude extracts were made by lysis of the fungi. As many of these fungi produce bioactive substances , the toxicity was determined. It was important to determine the cytotoxicity of the extracts because the goal of an anti-HIV-1 drug screen is to maintain cell viability while eliminating or inhibiting the virus. A large number of extracts proved to be toxic, however 100 of them showed low enough toxicity levels (< 30%) to continue with further studies (Fig. 3a). The antiviral capability of these extracts was determined by assessing their effects on viral replication in an infected A3.01 cell culture. While many extracts did not display any negative effects on viral replication, a few promising ones were discovered (Fig. 1). The fact that these crude extracts were able to inhibit HIV-1 replication suggested that one or more compounds within the extracts were affecting the viral lifecycle at some point. To this end, the promising extracts were fractionated in order to isolate these individual compounds. Several rounds of fractionation were carried out and the fractions were evaluated for toxicity and antiviral effects after every round. The fractions that were non-toxic and inhibited HIV-1 replication were further fractionated until single compounds were isolated. The end result of the fractionations was the isolation of four compounds from endophytic fungal extracts that almost completely inhibited viral replication (Fig. 5b). This level of inhibition is comparable to that seen with the use of the antiretroviral drug AZT, which has been used for decades to treat an HIV-1 infection. While the calculated therapeutic indexes for the compounds isolated in this study are low, it does provide a narrow window to further explore the use of these compounds as a possible method of treatment. These studies demonstrate that not only can endophytic fungi be a useful source for anti-HIV drug discovery, but these fungi can also provide very potent inhibitors that can possibly out-perform drugs in use today.
From a mechanistic standpoint, these studies have shown that the isolated compounds do not act by inhibiting the viral reverse transcriptase enzyme (Table 1). However, the effect of the inhibitory compounds on HIV-1 entry and protease enzyme function remains to be determined. It is possible, nonetheless, that these compounds function to inhibit viral replication through a novel mechanism, as they were isolated from a novel source. Regardless of the mechanism, these compounds are not toxic to cells at effective concentrations that inhibit the virus, which would suggest that there is more of an effect on viral proteins than cellular ones. A thorough characterization is underway to fully understand these compounds and how they function to inhibit HIV-1 replication.
A majority of the currently available anti-retroviral drugs targets the viral enzymes protease and reverse transcriptase. While these drugs are effective at reducing viral replication, they result in many unpleasant side effects and the eventual emergence of drug-resistant viral strains is a problem . This highlights the need for development of new anti-HIV drugs, if the HIV-1 epidemic is to be successfully contained. Our studies evaluating endophytic fungal extracts resulted in promising new possibilities for the discovery of novel anti-HIV-1 drugs by isolating four compounds that inhibit viral replication. In addition, as these inhibitors originated from a previously unexplored resource, the mechanism of action for these new compounds may also prove to be novel. Taken together, these studies could provide new weapons to fight the war on HIV-1 and AIDS.
Production of Crude Extracts from Endophytic Fungi
Several hundred endophytic fungal strains from desert plants were grown on either solid or liquid media cultures. Solid media cultures of fungal strains were processed by adding methanol to each growth flask, followed by sonication in an ultrasonic bath to kill the organism, and filtration through Celite-545. The filtrate was concentrated under vacuum to half in volume, extracted with ethyl acetate, dried over anhydrous sodium sulfate and evaporated to obtain the crude extracts. Liquid media cultures were extracted with ethyl acetate, dried, and evaporated under vacuum to yield crude extracts. We first determined the cytotoxicity of these abstracts and found that 100 fungal extracts showed less than 30% cytotoxicity. These non-toxic fungal extracts were evaluated for their ability to inhibit HIV-1 replication in T-lymphocytes. The endophytic fungal species which produced extracts that showed maximum inhibition of HIV-1 replication were identified; extract B was derived from a Phoma-like fungal strain inhabiting the root tissue of an unidentified Ephedra species, extract G was derived from the endophytic fungal species Alternaria tenuissima inhabiting the stem of the Sonoran desert plant Quercus emoryi, extract I was derived from an Aspergillus species inhabiting the stem tissue of Caesalpinia gilliesii.
Fractionation of Endophytic Fungal Extracts
Crude extracts that were not cytotoxic but inhibited HIV-1 replication were fractionated several times to isolate the individual compounds present within each extract. In order to generate enough crude extracts to proceed with fractionation, previous cultures that yielded active crude extracts were grown on a large scale and the crude extracts were again isolated, with large scale extracts CZ and DA originating from large scale culture of the culture that yielded B, large scale extract DB originating from large scale culture of the culture that yielded G, and large scale extract DC originating from large scale culture of the culture that yielded I. Fractionation was performed using a combination of solvent-solvent partitioning and Sephadex LH-20 Gel permeation chromatography on large scale liquid media cultures . Briefly, liquid cultures (10 L) were filtered through Whatman No. 1 filter paper. The yellow filtrate (10 L) was extracted with ethyl acetate (EtOAc) (4 x 2 L) and evaporated under reduced pressure to afford a dark yellow residue (530 mg). Second batch liquid culture (10 L) under similar conditions gave another EtOAc extract (870 mg). The EtOAc extracts were combined (1.4 g) (DB) and partitioned between hexane and 80% aqueous methanol (MeOH). The 80% aqueous MeOH fraction was diluted to 50% by the addition of H2O and extracted with CHCl3. Evaporation of the CHCl3 fraction under reduced pressure yielded dark residue (DB-2) (595.3 mg). A portion (550 mg) of DB-2 was subjected to gel permeation chromatography on a column of Sephadex LH–20 (20 g) in hexane–CH2Cl2 (1:4) and eluted with 300 mL each of hexane–CH2Cl2 (1:4), CH2Cl2–acetone (3:2), CH2Cl2–acetone (1:4), CH2Cl2–MeOH (1:4), and MeOH. Six fractions were collected, including the active fractions: DD (72.2 mg), DE (56.8 mg), DF (102.5 mg), and DG (114.8 mg). Column chromatography of fraction DD (72.2 mg) on lichroprep diol Si gel (4 g) by elution with CH2Cl2 followed by preparative TLC on normal phase silica gel (IPA–CH2Cl2, 3:97) afforded compound DK (1.9 mg). Purification of fraction DE (56.8 mg) by column chromatography on normal phase Si gel by elution with increasing amounts of acetone in CH2Cl2 afforded compound DL (15.0 mg). Column chromatography of fraction DF (102.5 mg) on normal phase Si gel (4.0 g) by elution with increasing amounts of acetone in CH2Cl2 followed by preparative TLC on normal phase Si gel (IPA–CH2Cl2, 3:97) afforded compound DM, (3.1 mg), DN (3.7 mg), DP (11.2 mg). The purity of all isolated compounds was shown to be over 95% by chromatographic and spectroscopic analysis. The techniques used included thin-layer chromatography (TLC), and ultra-violet (UV), infrared (IR), nuclear magnetic resonance (NMR), and mass spectroscopy (MS). Identification of all known compounds involved comparison of their spectroscopic data (NMR and MS) with those reported.
Culture of Cell Lines
All cell lines and viruses used in this study were obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. A3.01 cells, a T4-lymphocyte cell line known to support HIV-1 infection, were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 50U/mL penicillin and 50μg/mL streptomycin (Invitrogen). Cells were fed every three days with fresh media.
Evaluation of Cytotoxicity of Antiviral Extracts, Fractions, and Compounds
MTT assays were used to determine the cytotoxicity of the crude extracts, fractions, and compounds used in this study. Briefly, the tetrazolium salt MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide] is metabolized by mitochondrial succinic dehydrogenase activity of proliferating cells to yield a formazan reaction product. To evaluate the cytotoxicity of the extract, A3.01 cells were plated in 96-well plates at a concentration of 2x105 cells/well. The cells were incubated with the desired concentration of extract, fraction, or compound for a period of 3, 6, and 9 days. On the day of the cytotoxicity assay, MTT (Sigma) was added to each well to a final concentration of 700 ng/µL. After at 4 hours at 37°C, the media was removed and the cells were lysed using DMSO (Sigma), solubilizing the formazan product. The color intensity was estimated in a microtitre plate reader (wavelength of 570 nm). For extended cultures, cells were given fresh media and extract, fraction or compound every three days.
Effect of Antiviral Extracts, Fractions, and Compounds on HIV-1 Replication
A3.01 cells were plated at a density of 5 x 105 cells/well in RPMI containing no serum. Extracts to be tested were added at a final concentration of 2 μg/mL for initial screening. For experiments testing fractionated extracts, the concentrations used were based off of cytotoxicity results. A control using DMSO was included in each experiment at the concentration present in the working solution of the extracts. Controls with azidothymidine (AZT) (Sigma-Aldrich) at concentrations of 10 μM and 20 μM were also performed in all experiments. The lab-adapted HIV-1 viral isolate LAV was used in all experiments. For infections, the virus was added at a concentration of 50,000 reverse-transcriptase (RT) counts per well, resulting in a calculated multiplicity of infection (MOI) of approximately 0.005 . The virus was allowed to adsorb for two hours, at which time any unadsorbed virus was removed. The cells were washed with phosphate buffered saline (PBS), and given fresh media containing serum and the extract, fraction, or compound at the desired concentration. Fresh media and extract were given to the cells every three days for 18 days. The culture supernatant that was removed every three days, stored, and the amount of progeny virions present was determined by reverse-transcriptase (RT) assay. Infections were done in duplicate wells per experiment, and each experiment was done in duplicate.
The levels of HIV-1 in culture were determined via reverse transcriptase (RT) assay . Briefly, the RT assay consisted of mixing culture supernatant with RT cocktail (94mM KCl, 5mM DTT, 63 mg poly-A DNA, 63mM Tris pH 7.8, 6mM MgCl2, 6μg oligo-dT DNA, 0.06% NP-40, 0.1% Triton-X), which contains 32P-dTTP (800Ci/mmol). The reaction was incubated at 37°C for 2 hours, and then spotted onto DE81 paper (Whatman), which was rinsed in 2x SSC buffer (Invitrogen) to remove unincorporated radioactivity. The amount of 32P present was determined using a scintillation counter (Beckman). The amount of virus present in the culture was then expressed as counts per minute (cpm).
CONFLICT OF INTEREST
The authors confirm that this article content has no conflict of interest.
This work was supported by a grant from the Arizona Biomedical Research Commission (contract #9014).